|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 907.30 INR | -0.35% |
|
+2.34% | -0.69% |
| Feb. 11 | India's Zydus, US unit settle Mirabegron patent dispute with $120 million payment | RE |
| Feb. 11 | Zydus Lifesciences enters settlement agreement with Astellas over Myrbetriq | RE |
Main competitors
| P/E (Y) | Price to Book (Y) | PEG (Y) | EV / Sales (Y) | EV / EBITDA (Y) | EV / EBIT (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|
 | 20.03x | 3.27x | 45.84x | 3.42x | 12.86x | 15.56x | 0.9% | 10.05B | |
| 34.91x | 5.06x | 5.26x | 6.62x | 22.72x | 27.59x | 0.87% | 44.97B | |
| 16.71x | 1.9x | -214.78x | 2.15x | 8.93x | 11.58x | 1.35% | 36.57B | |
| 25.67x | 3.12x | -1.25x | 3.46x | 16.37x | 20.18x | 1.03% | 11.88B | |
| 17.31x | 3.2x | 1.02x | 3.25x | 12.03x | 14.56x | 3.42% | 8.5B | |
| 84.35x | 6.54x | 7.35x | - | - | - | 1.06% | 8.19B | |
| 17.31x | 1.46x | 0.46x | 2.24x | 8.68x | 11.33x | 3.07% | 7.8B | |
| 9.35x | 1.52x | -2.2x | 2.02x | 5.45x | 6.53x | 4.52% | 6.68B | |
| 31.52x | 5.45x | 0.45x | 3.4x | 15.46x | 16.2x | 0.14% | 6.22B | |
| 46.8x | 6.33x | 1.37x | 5.09x | 23.03x | 32.11x | 0.18% | 5.28B | |
| 23.54x | 3.6x | 0.35x | 3.81x | 18.13x | 22.04x | 2.17% | 4.26B | |
| 34.39x | 8.1x | 2.22x | 6.62x | 24.37x | 27.19x | 1.14% | 4.03B | |
| 10.8x | 0.62x | -0.02x | 1.9x | 7.94x | 9.63x | 1.93% | 3.48B | |
| 16.04x | 3.71x | 0.87x | 3.78x | 13.53x | 14.84x | 2.5% | 2.99B | |
| 19.22x | 5.28x | 0.54x | 6.13x | 17.5x | 18.61x | 3.12% | 2.49B | |
| Average | 27.20x | 3.94x | -10.17x | 3.85x | 14.79x | 17.71x | 1.83% | 10.89B | |
| Weighted average by Cap. | 27.78x | 3.74x | -43.40x | 4.09x | 15.36x | 18.78x | 1.46% |
- Stock Market
- Equities
- ZYDUSLIFE Stock
- Sector Zydus Lifesciences Limited
- Sector valuations
Select your edition
All financial news and data tailored to specific country editions
